BioNexus Gene Lab Corp.

As of December 9, 2022, BioNexus Gene Lab Corp. is considered overvalued and risky due to negative valuation ratios, poor performance metrics, and a significant decline in long-term returns despite strong short-term gains.

As of December 9, 2022, BioNexus Gene Lab Corp. is considered overvalued and risky due to significant financial challenges, a low EV to Sales ratio of 0.22, a negative EV to EBITDA ratio of -0.95, and a poor 1-year stock return of -41.01%, contrasting with the S&P 500's 10.26% return.

As of June 11, 2025, the technical trend has shifted to mildly bearish due to bearish signals from daily moving averages and weekly Bollinger Bands, despite some mildly bullish indicators on the MACD and KST.

BioNexus Gene Lab Corp. is a micro-cap company in the miscellaneous industry, reporting net sales of $2 million and a net loss of $1 million for Q1 2025. Key metrics include a market cap of $5.17 million, a debt equity ratio of -0.46, and a return on equity of -27.32%.

As of Jun 18, BioNexus Gene Lab Corp. has a market capitalization of 5.17 million and reported net sales of 9.26 million with a net profit of -2.12 million over the last four quarters.